Rosemont Pharmaceuticals to acquire Aytu BioPharma for $2.70 a share in cash
The all-cash tender offer, announced November 16, 2026, carries premiums over recent trading prices, with closing expected by year end.
Aytu BioPharma, Inc. (Nasdaq: AYTU) said on November 16, 2026 that it had entered into a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc., under which Rosemont would acquire Aytu through a tender offer for $2.70 per share in cash.1 The offer price represents a 41.1% premium to the 30-day volume-weighted average price and a 51.7% premium to the closing price on November 13, 2026.1
Under the deal structure, a wholly-owned subsidiary of Rosemont will commence a tender offer for all outstanding Aytu shares, to be followed by a merger, subject to customary conditions including tender of a majority of outstanding shares and resolution of certain outstanding warrants.1 Any shares not tendered would then be acquired through a second-step merger at the same price.1
Rosemont intends to file a Schedule TO within 10 business days, with Aytu filing a Schedule 14D-9 around the same time.1 The Aytu board unanimously approved the transaction, and closing is anticipated in late December 2026, subject to satisfaction or waiver of tender offer conditions.1 Aytu's executive officers, directors, and stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management signed support agreements to tender their shares.1
Per the separately filed 8-K, the offer is structured through an Agreement and Plan of Merger with Rosemont Pharmaceuticals Holdings, Inc. and RoseApollo Merger Sub, Inc., a wholly owned Rosemont subsidiary.1 Consummation of the offer is not subject to a financing condition.1 The agreement includes termination rights if the offer is not completed by February 14, 2027, and a $2.4 million termination fee payable by Aytu under specified circumstances.1
Canaccord Genuity is advising Aytu, with Dorsey & Whitney as legal counsel; Bourne Partners is advising Rosemont, with Ropes & Gray as legal counsel.1 Rosemont Pharmaceuticals, headquartered in Leeds, UK, specializes in oral liquid medicines.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.